# Gap Analysis: MedUni Wien vs. Existing Ch15 Coverage

**Comparison Date:** 2026-02-03
**Sources:**
- MedUni Wien Indikations-Medikamentenliste (2025-02-21)
- MedUni Wien "Care for ME/CFS" Praxisleitfaden (2024)
- Existing ch15-medications-systems.tex

---

## Medications ALREADY COVERED in Ch15

### Well-Documented
| Medication | MedUni Wien Category | Ch15 Section | Coverage Quality |
|------------|---------------------|--------------|------------------|
| Low-Dose Naltrexone (LDN) | Cognitive dysfunction | §15.1 | Excellent (mechanism, dosing, warnings) |
| Low-Dose Aripiprazole (LDA) | Cognitive dysfunction | §15.7.4 | Excellent (with metabolic monitoring) |
| Pyridostigmine (Mestinon) | Orthostatic intolerance | §15.6 | Excellent (dosing, mechanism) |
| Ivabradine | PoTS tachycardia | §14b (action protocols) | Good (mechanism, dosing) |
| Beta-blockers (Nebivolol) | PoTS tachycardia | §15 (autonomic section) | Good |

### Partially Covered
| Medication | MedUni Wien Category | Ch15 Status | Gap |
|------------|---------------------|-------------|-----|
| H1/H2 blockers | MCAS | Mentioned | Need specific MCAS protocol section |
| Statins (Atorvastatin) | Endothelial dysfunction | Brief mention | Need endothelial dysfunction section |
| Aspirin (TASS 50mg) | Microthrombi | Brief mention | Need microthrombi/circulation section |

---

## GAPS: Medications NOT in Ch15

### High Priority (Evidence from Praxisleitfaden data)

1. **Fluvoxamine**
   - **MedUni Wien indication:** Cognitive dysfunction, depression, obsessive thoughts
   - **Gap:** Not mentioned in ch15
   - **Evidence:** SSRI with anti-inflammatory properties; COVID-19 studies suggest benefit
   - **Integration target:** §15.7 (cognitive medications) or §15.4 (antiviral/anti-inflammatory synergies)

2. **Guanfacin + N-Acetylcysteine combination**
   - **MedUni Wien indication:** Cognitive dysfunction (not for children)
   - **Gap:** Not mentioned in ch15
   - **Mechanism:** Alpha-2A agonist (prefrontal cortex function) + antioxidant
   - **Integration target:** §15.7 (cognitive medications)

3. **Ketotifen**
   - **MedUni Wien indication:** Mast cell stabilization
   - **Gap:** Not mentioned in ch15
   - **Evidence:** Stronger than cromolyn; lipophilic crosses BBB
   - **Integration target:** Need new §15.X (MCAS medications)

4. **Cromolyn sodium (Cromoglicinsäure)**
   - **MedUni Wien indication:** Mast cell stabilization
   - **Gap:** Not mentioned in ch15
   - **Evidence:** Well-established mast cell stabilizer
   - **Integration target:** Need new §15.X (MCAS medications)

5. **Midodrine (Gutron)**
   - **MedUni Wien indication:** Orthostatic intolerance/PoTS
   - **Gap:** Not mentioned in ch15
   - **Mechanism:** Alpha-1 agonist; increases peripheral vascular tone
   - **Integration target:** §15.6 (autonomic medications)

6. **Fludrocortisone (Astonin H)**
   - **MedUni Wien indication:** Orthostatic intolerance/PoTS
   - **Gap:** Not mentioned in ch15
   - **Mechanism:** Mineralocorticoid; increases blood volume
   - **Integration target:** §15.6 (autonomic medications)

### Medium Priority (Common clinical use)

7. **Ginkgo extract (Cerebokan 80mg)**
   - **MedUni Wien indication:** Endothelial dysfunction, microthrombi
   - **Gap:** Not mentioned in ch15
   - **Evidence:** Improves microcirculation
   - **Integration target:** New §15.X (endothelial/circulatory medications)

8. **Sulodexide**
   - **MedUni Wien indication:** Microthrombi, circulatory disturbances
   - **Gap:** Not mentioned in ch15
   - **Evidence:** Glycosaminoglycan with antithrombotic properties
   - **Integration target:** New §15.X (endothelial/circulatory medications)

9. **Clopidogrel**
   - **MedUni Wien indication:** Microthrombi
   - **Gap:** Not mentioned in ch15
   - **Evidence:** ADP receptor antagonist
   - **Integration target:** New §15.X (endothelial/circulatory medications)

10. **Magnosolv and Dioscomb**
    - **MedUni Wien indication:** Endothelial dysfunction, proBNP elevation
    - **Gap:** Not mentioned in ch15
    - **Note:** These appear to be European herbal/supplement products
    - **Integration target:** Ch16 (supplements) or new section

---

## SECTIONS NEEDED in Ch15

### 1. New Section: MCAS Medication Protocol
**Location:** After §15.6 (autonomic) → New §15.7 (MCAS)
**Content:**
- H1/H2 blocker combinations
- Ketotifen (mechanism, dosing)
- Cromolyn sodium (mechanism, dosing)
- Diagnostic criteria reference (MCAS diagnosis required)

### 2. New Section: Endothelial Dysfunction & Microthrombi
**Location:** After MCAS section → New §15.8
**Content:**
- Rationale (microclots hypothesis, endothelial damage in ME/CFS)
- Antiplatelet agents (aspirin, clopidogrel)
- Glycosaminoglycans (sulodexide)
- Statins for endothelial protection
- Ginkgo for microcirculation

### 3. Expand: Cognitive Medications Section
**Location:** Current §15.7.4 (LDA) → Expand to §15.7 (Cognitive Medications)
**Add:**
- Fluvoxamine (SSRI with anti-inflammatory properties)
- Guanfacin + NAC combination
- Treatment sequencing (LDA → LDN → Mestinon already covered)

### 4. Expand: Autonomic Medications Section
**Location:** Current §15.6 (Mestinon/Pyridostigmine)
**Add:**
- Midodrine (alpha-1 agonist)
- Fludrocortisone (volume expansion)
- Treatment algorithm for PoTS severity tiers

---

## CROSS-REFERENCES NEEDED

### To Chapter 4 (Diagnostic)
- Add reference to MedUni Wien diagnostic algorithm
- Cross-reference to MCAS diagnostic criteria (for medication eligibility)
- Cross-reference to PoTS testing (Schellong, tilt table) for medication selection

### To Appendix H (Bibliography)
- Add MedUni Wien Praxisleitfaden (2024)
- Add MedUni Wien Medication List (2025-02-21)
- Add Austrian D-A-CH Consensus Statement reference

---

## KEY PRINCIPLES FROM MEDUNI WIEN TO INTEGRATE

From the Praxisleitfaden medication table (p. 16):

1. **Start low, go slow:** Begin with lowest dose, gradual titration
2. **Most effective medications target comorbidities:**
   - MCAS medications: 32-48% report improvement
   - PoTS medications: 27-39% report improvement
   - Cognitive medications (LDN/LDA): 22-33% improvement
3. **High non-response rates:** 51-77% report NO improvement for most medications
4. **Analgesics largely ineffective:** 60-71% no improvement; high adverse effects
5. **Antidepressants largely ineffective:** 67-77% no improvement; not indicated unless comorbid depression

**CRITICAL NOTE:** The Praxisleitfaden data (CCCFS survey) strongly supports **targeting comorbidities** (MCAS, PoTS, immunedeficiency) rather than core ME/CFS symptoms directly.

---

## INTEGRATION PRIORITIES

### Tier 1 (Immediate)
1. Create MCAS medications section (ketotifen, cromolyn)
2. Expand autonomic section (midodrine, fludrocortisone)
3. Add fluvoxamine to cognitive medications

### Tier 2 (Soon)
4. Create endothelial/microthrombi section
5. Add guanfacin + NAC combination
6. Add cross-references to ch04 diagnostic criteria

### Tier 3 (Lower priority)
7. Evaluate Magnosolv/Dioscomb (may be European supplements → ch16)
8. Add sulodexide, clopidogrel details
9. Ginkgo extract (borderline supplement/medication)

---

## CERTAINTY ASSESSMENT

**MedUni Wien Resources:**
- **Quality:** High (institutional guideline from major academic medical center)
- **Currency:** Very current (2024 Praxisleitfaden, 2025-02-21 medication list)
- **Scope:** D-A-CH region (Germany, Austria, Switzerland)
- **Limitations:** Off-label use only; insurance coverage Austria-specific
- **Evidence Base:** Mix of clinical experience + CCCFS patient survey (n=687)

**Recommendation:** Cite as institutional clinical guideline with regional context (Austrian health system).
